Inhibrx Inc stock (US45720L1070): Biotech firm in Virtus ETF holdings

Inhibrx Inc (INBX), a clinical-stage biotech developing precision therapies, ranks among top holdings in the Virtus Biotech Clinical Trials ETF (BBC) as of recent data, highlighting its role in clinical innovation for US investors.

Inhibrx Inc, trading as INBX, maintains a position in the top 25 holdings of the Virtus LifeSci Biotech Clinical Trials ETF (BBC), which tracks companies advancing biotech clinical trials. This placement underscores Inhibrx's ongoing pipeline in precision oncology and immunology, according to StockAnalysis.com as of 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Inhibrx Biosciences, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: US, global pharma
• Key revenue drivers: Clinical pipeline, partnerships
• Home exchange/listing venue: Nasdaq (INBX)
• Trading currency: USD

Inhibrx Inc: core business model

Inhibrx Inc develops protein therapeutics using its proprietary protein scaffolding platform, focused on oncology, immunology, and rare diseases. The company engineers protein constructs to target challenging disease pathways with high specificity. This approach aims to create differentiated therapies for unmet medical needs, as detailed on its official website.

Headquartered in San Diego, California, Inhibrx advances multiple candidates through clinical stages, emphasizing precision medicine. Its platform allows modular design of multi-specific proteins, potentially improving efficacy and safety profiles over traditional biologics.

Main revenue and product drivers for Inhibrx Inc

Key assets include INBRX-109, a precision oncology drug targeting death receptor 5 for solid tumors, currently in Phase 1 trials. Additional programs address fibrotic diseases and inflammatory conditions. Revenue stems primarily from collaboration deals and milestone payments, with potential from future approvals.

The company's inclusion as the 16th largest holding in the BBC ETF reflects investor interest in its clinical progress, per StockAnalysis.com as of 2026. This ETF focuses on biotech firms in active trials, providing US investors exposure to innovation pipelines.

Industry trends and competitive position

Biotech clinical trials remain a high-growth area, with the sector deploying significant capital amid advances in precision medicine. Inhibrx competes with firms like Relay Therapeutics (RLAY) and Intellia Therapeutics (NTLA), also in BBC holdings. Its protein engineering differentiates it in targeted therapy development.

Why Inhibrx Inc matters for US investors

Listed on Nasdaq, Inhibrx offers US investors direct access to cutting-edge biotech via familiar trading venues. Its ETF presence in BBC enhances visibility and liquidity potential, aligning with portfolios seeking clinical-stage exposure amid a robust US pharma market.

Conclusion

Inhibrx Inc continues to advance its protein therapeutics platform, with ETF inclusion signaling market recognition of its clinical efforts. US investors track such biotechs for growth potential tied to trial outcomes and partnerships. Developments remain key to watch amid sector volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.